Morningside Venture Investments Ltd
Morningside Venture Investments Ltd's purchase track record
Morningside Venture Investments Ltd has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/3/2026 | APMD | $5.00M | pending | pending | — |
| 1/11/2022 | AMLX | $5.00M | -41.2% | +4.4% | -19.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Transaction History
| APMD | ▼ Sell | Other | 6,840,213 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 6,840,213 | — | 8/3/2026 | View on chart |
| APMD | ▲ Buy | Open Market | 312,500 | $5.0M | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 75,624 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 75,624 | — | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 75,624 | $1.1M | 8/3/2026 | View on chart |
| APMD | ▼ Sell | Other | 6,840,213 | — | 8/3/2026 | View on chart |
| AMLX | ▼ Sell | Gift | 2,000,000 | $0 | 8/15/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 29,048 | $885K | 3/29/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 100,000 | $3.0M | 3/28/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 32,964 | $997K | 3/27/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 28,000 | $862K | 3/27/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 34,641 | $1.1M | 3/21/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 28,807 | $927K | 3/21/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 9,122 | $297K | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 108,934 | $3.6M | 3/15/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 41,066 | $1.4M | 3/15/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 70,714 | $2.4M | 3/14/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 50,000 | $1.7M | 3/2/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 48,889 | $1.7M | 2/23/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,111 | $40K | 2/23/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 47,888 | $1.7M | 2/22/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 2,112 | $75K | 2/22/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 39,916 | $1.4M | 2/22/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 10,084 | $366K | 2/22/2023 | View on chart |
| AMLX | ▼ Sell | Other | 10,415,650 | — | 1/11/2022 | View on chart |
| AMLX | ▲ Buy | Open Market | 263,158 | $5.0M | 1/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Apnimed to Present Five Abstracts at CHEST 2026
Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.
Apnimed to Present Five Abstracts at CHEST 2026. Apnimed announced it will present five abstracts, including two late-breaking studies, at the CHEST 2026 conference. This highlights the company's ongoing research activity and clinical data generation. The stock currently trades well below its 52-week high, with an average analyst target of $50.33.